NeuroSense Therapeutics Ltd. vs Nasus Pharma Ltd. — Valuation Comparison 2026
Access all valuation models for NRSN vs NSRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →NRSN scores higher with a 3.8/10 quality rating vs NSRX's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing NeuroSense Therapeutics Ltd. (NRSN) and Nasus Pharma Ltd. (NSRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
NRSN currently trades at $0.82 with a QOC of 3.8/10, while NSRX trades at $3.36 with a QOC of 1.9/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).